These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28122792)

  • 1. With regard to the papers by Kumar et al. and de Leeuw and de Boer addressing the cardiovascular safety and efficacy of anti-diabetic drugs.
    Turner JR; Caveney E; Gillespie BS; Karnad DR; Kothari S; Metz A; Keller LH
    Eur Heart J Cardiovasc Pharmacother; 2017 Apr; 3(2):75-76. PubMed ID: 28122792
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular safety of anti-diabetic drugs.
    Kumar R; Kerins DM; Walther T
    Eur Heart J Cardiovasc Pharmacother; 2016 Jan; 2(1):32-43. PubMed ID: 27533060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular safety of non-insulin pharmacotherapy for type 2 diabetes.
    Xu J; Rajaratnam R
    Cardiovasc Diabetol; 2017 Feb; 16(1):18. PubMed ID: 28148253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cardiovascular safety of non-insulin anti-diabetic drugs. Scientific position statement of SEMERGEN].
    Prieto MÁ; Comas Samper JM; Escobar Cervantes C; Gasull Molinera V
    Semergen; 2014; 40(5):261-73. PubMed ID: 24882393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis Addressing the Cardiovascular Safety of Bexagliflozin in Patients With Type 2 Diabetes Mellitus.
    Patoulias D; Dimosiari A
    Am J Cardiol; 2022 Sep; 178():178-179. PubMed ID: 35773042
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cardiovascular safety of new type 2 diabetes drugs].
    Hormigo Pozo A; Mancera Romero J
    Semergen; 2014 Mar; 40(2):55-6. PubMed ID: 24655909
    [No Abstract]   [Full Text] [Related]  

  • 7. Drugs for type 2 diabetes mellitus: the imperative for cardiovascular outcome assessment.
    Gore MO; McGuire DK
    Diab Vasc Dis Res; 2012 Apr; 9(2):85-8. PubMed ID: 22496441
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter by Wang et al Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks".
    Wang D; Chen T; Yang X
    Circulation; 2019 Oct; 140(16):e720-e721. PubMed ID: 31609657
    [No Abstract]   [Full Text] [Related]  

  • 9. Newer glucose-lowering drugs and risk of dementia: A meta-analysis of cardiovascular outcome trials.
    Tang H; Niu S; Brown J; Wei J; Shao H; Bian J; Guo J
    J Am Geriatr Soc; 2022 Sep; 70(9):2719-2722. PubMed ID: 35612586
    [No Abstract]   [Full Text] [Related]  

  • 10. [The influence of drugs used in the treatment of diabetes type 2 on the cardio-vascular risk].
    Kern A; Zaleska M; Możeńska O; Bil J
    Wiad Lek; 2017; 70(4):827-833. PubMed ID: 29064812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes medications and cardiovascular outcome trials: Lessons learned.
    Patel KV; de Albuquerque Rocha N; McGuire DK
    Cleve Clin J Med; 2017 Oct; 84(10):759-767. PubMed ID: 28985176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular effects of some antidiabetic drugs.
    Med Lett Drugs Ther; 2017 Aug; 59(1527):136-138. PubMed ID: 28787745
    [No Abstract]   [Full Text] [Related]  

  • 13. Cardiovascular Safety of Current and Emerging Glucose-Lowering Therapies.
    Fitchett D
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S176-82. PubMed ID: 26654861
    [No Abstract]   [Full Text] [Related]  

  • 14. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
    Hiatt WR; Kaul S; Smith RJ
    N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
    [No Abstract]   [Full Text] [Related]  

  • 15. Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.
    Yandrapalli S; Jolly G; Horblitt A; Sanaani A; Aronow WS
    Postgrad Med; 2017 Nov; 129(8):811-821. PubMed ID: 28749197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incretins: cardiovascular safety and rationale for use.
    Kok A
    Cardiovasc J Afr; 2013 Mar; 24(2):46. PubMed ID: 23750348
    [No Abstract]   [Full Text] [Related]  

  • 17. [Cardiovascular effects and safety of glucose-lowering drugs: current situation].
    Masmiquel L
    Semergen; 2014 Mar; 40(2):80-8. PubMed ID: 24655910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety of type 2 diabetes medications: Review of existing literature and clinical implications.
    Paredes S; Matta-Coelho C; Monteiro AM; Brás A; Marques O; Alves M; Ribeiro L
    Hormones (Athens); 2016 Apr; 15(2):170-185. PubMed ID: 27376421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Oral antidiabetic therapy and cardiovascular complications: theoretical problem or clinical evidence?].
    Pogátsa G
    Orv Hetil; 2003 Apr; 144(14):645-50. PubMed ID: 12795025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of diabetes drugs: making the dark ages brighter with Carolina.
    Rosenstock J; Marx N; Johansen OE; Wörle HJ;
    Ann Intern Med; 2013 Mar; 158(6):499. PubMed ID: 23553039
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.